OncoZenge raises MSEK 10 ahead of spin-off and separate listing
OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has today resolved on a directed share issue in accordance with the press release from November 16[th], 2020 (the “Directed Issue”). The Directed Issue of MSEK 10 is the first step of the secured financing in OncoZenge of MSEK 70 in total. The share issue is carried out to secure OncoZenge’s initial working capital requirements ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021.On November 16[th], 2020, it was announced that OncoZenge, through